AGCO Corporation vs Cassava Sciences Inc — how do they compare? AGCO Corporation trades at $102.25 (market cap $7.10B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: AGCO Corporation is far larger — about 148.7× Cassava Sciences Inc's market cap, and AGCO Corporation pays a 1.18% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| AGCO | FLNA | |
|---|---|---|
Market Cap | $7.10B | $47.75M |
Sector | Industrials | Health |
52-Week High | $140.49 | $4.64 |
52-Week Low | $100.14 | $0.87 |
Enterprise Value | $9.37B | -$34.93M |
Dividend Yield | 1.18% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Trailing returns across standard periods
Latest headlines on both assets
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →